FDA Lifts Clinical Hold on LogicBio Therapeutics' IND for LB-001 in pediatric patients with Methylmalonic Acidemia

 

The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on LogicBio Therapeutics’ LOGC Investigational New Drug Application (IND) of its drug candidate LB-001 for pediatric patients with methylmalonic acidemia.

This regulatory action allows patient enrollment to resume in the Phase 1/2 SUNRISE investigating LB-001.

FDA indicated in its acknowledgement that LogicBio has satisfactorily addressed all clinical hold issues.

Frederic Chereau, president and chief executive officer, said, "We are pleased that the FDA has completed its review of the information we provided and that the hold on our LB-001 IND has been lifted, We look forward to dosing the next patient in our SUNRISE trial, which we expect will occur in the third quarter of 2022."

Earlier, the clinical hold was enforced by FDA following the occurrence of two serious adverse events, termed as cases of thrombotic microangiopathy (TMA). Both cases of TMA resolved within week.

As the study progressed, the company expects to present interim clinical data from the SUNRISE trial by the end of the second quarter of 2022.

LogicBio Therapeutics is trading up 54 percent at $0.77 in the pre-market session.

Posted In: Information TechnologySemiconductorsBiotechNewsPenny StocksHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.